Compare FPF & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPF | COLL |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2015 |
| Metric | FPF | COLL |
|---|---|---|
| Price | $18.14 | $34.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $50.83 |
| AVG Volume (30 Days) | 119.0K | ★ 400.6K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 8.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $6.07 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.21 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $15.60 | $23.23 |
| 52 Week High | $19.75 | $50.79 |
| Indicator | FPF | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 26.78 | 16.51 |
| Support Level | N/A | $34.30 |
| Resistance Level | $18.95 | $36.20 |
| Average True Range (ATR) | 0.19 | 1.59 |
| MACD | -0.10 | -0.70 |
| Stochastic Oscillator | 0.80 | 2.18 |
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.